HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

YMAB

Y-Mabs Therapeutics Inc

Last Close
Dec 11 • 04:00PM ET
10.01
Dollar change
-0.27
Percentage change
-2.63 		%
Healthcare • Biotechnology • USA • NASD
Peers: BMRN CLLS BLUE ADAP AGEN SRPT MRNA GSK TGTX XOMA
 | Held by: VTI IWM VXF XBI IWO IBB VTWO SCHA VHT IWC
Scroll to Statements
IndexRUT P/E- EPS (ttm)-0.54 Insider Own16.99% Shs Outstand44.77M Perf Week-3.56%
Market Cap448.34M Forward P/E- EPS next Y-0.61 Insider Trans-2.82% Shs Float37.18M Perf Month-32.68%
Income-23.86M PEG- EPS next Q-0.12 Inst Own60.19% Short Float10.33% Perf Quarter-24.40%
Sales84.55M P/S5.30 EPS this Y-30.68% Inst Trans6.69% Short Ratio15.87 Perf Half Y-16.72%
Book/sh2.06 P/B4.85 EPS next Y5.25% ROA-19.11% Short Interest3.84M Perf Year50.30%
Cash/sh1.52 P/C6.58 EPS next 5Y- ROE-24.78% 52W Range6.09 - 20.90 Perf YTD46.77%
Dividend Est.- P/FCF- EPS past 5Y20.06% ROI-25.74% 52W High-52.11% Beta0.62
Dividend TTM- Quick Ratio3.54 Sales past 5Y37.03% Gross Margin88.83% 52W Low64.37% ATR (14)0.81
Dividend Ex-Date- Current Ratio3.92 EPS Y/Y TTM-22.45% Oper. Margin-33.66% RSI (14)32.47 Volatility6.58% 7.83%
Employees100 Debt/Eq0.01 Sales Y/Y TTM-8.99% Profit Margin-28.22% Recom1.50 Target Price20.58
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q11.71% Payout- Rel Volume0.69 Prev Close10.28
Sales Surprise-20.69% EPS Surprise-1.39% Sales Q/Q-9.74% EarningsNov 08 BMO Avg Volume241.90K Price10.01
SMA20-8.08% SMA50-23.48% SMA200-25.51% Trades Volume167,629 Change-2.63%
Date Action Analyst Rating Change Price Target Change
Nov-18-24Initiated Oppenheimer Outperform $23
Aug-16-24Initiated Cantor Fitzgerald Overweight $20
Jun-28-24Initiated Truist Buy $21
May-10-23Upgrade Wedbush Neutral → Outperform $5 → $13
Apr-03-23Downgrade Guggenheim Buy → Neutral
Jan-27-23Downgrade Morgan Stanley Equal-Weight → Underweight $4
Jan-05-23Downgrade Cowen Outperform → Market Perform
Dec-02-22Downgrade BofA Securities Buy → Neutral $23 → $5
Dec-02-22Downgrade BofA Securities Buy → Neutral
Oct-31-22Downgrade Wedbush Outperform → Neutral $6
Show Previous Ratings
Dec-07-24 12:00PM
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
(GlobeNewswire)
Nov-27-24 07:35AM
Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference
(GlobeNewswire) +10.31%
Nov-09-24 06:01AM
Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
(GuruFocus.com)
Nov-08-24 07:45AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
06:35AM
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
07:08AM Loading…
Nov-07-24 07:08AM
What To Expect From Y-mAbs Therapeutics Inc (YMAB) Q3 2024 Earnings
(GuruFocus.com)
Nov-04-24 07:35AM
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA (naxitamab-gqgk) in Japan
(GlobeNewswire)
Nov-01-24 10:00AM
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
(Zacks)
Oct-25-24 07:05AM
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
(GlobeNewswire)
Oct-09-24 06:12PM
Y-mAbs Therapeutics Inc (YMAB) Q2 2024 Earnings Call Highlights: Revenue Growth Driven by ...
(GuruFocus.com)
Oct-01-24 07:05AM
Y-mAbs to Participate in Upcoming Investor Conferences in October
(GlobeNewswire)
Sep-06-24 07:30AM
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
(GlobeNewswire)
Sep-03-24 08:32AM
Y-mAbs to Participate in Upcoming Investor Conferences in September
(GlobeNewswire)
Aug-12-24 06:33PM
Why Y-mAbs Therapeutics Stock Got Mashed on Monday
(Motley Fool) -11.24% +8.74%
07:40AM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
06:30AM Loading…
06:30AM
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Aug-09-24 07:20AM
Y-mAbs Therapeutics, Inc. (YMAB): One of Caligan Partners Top Holdings Now?
(Insider Monkey)
Aug-07-24 07:05AM
Y-mAbs to Participate in Upcoming Investor Conferences in August
(GlobeNewswire)
Aug-05-24 04:05PM
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
(GlobeNewswire) -6.27%
Jul-01-24 04:05PM
Y-mAbs Appoints Seasoned Biopharma Executive Peter Pfreundschuh as Chief Financial Officer
(GlobeNewswire)
Jun-07-24 07:05AM
Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting
(GlobeNewswire)
Jun-05-24 07:05AM
Y-mAbs Deepens Radiopharmaceutical Leadership with Appointment of Norman LaFrance, M.D. as Chief Development Officer
(GlobeNewswire) +5.91%
Jun-01-24 08:15AM
Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting
(GlobeNewswire)
08:05AM
Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting
(GlobeNewswire)
May-09-24 11:58AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call Transcript
(Insider Monkey) -5.44%
03:04AM
Y-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
May-08-24 09:57PM
Q1 2024 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) -20.92%
May-07-24 09:55PM
YMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024
(InvestorPlace)
06:12PM
Y-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue Estimates
(GuruFocus.com)
05:55PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
04:05PM Loading…
04:05PM
Y-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Apr-26-24 07:05AM
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
(GlobeNewswire)
Apr-25-24 04:05PM
Y-mAbs to Present at 2024 ASCO Annual Meeting
(GlobeNewswire)
Mar-28-24 09:55AM
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
(Zacks)
Mar-20-24 07:37AM
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
(Zacks)
Mar-14-24 09:05AM
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
(GlobeNewswire) -5.30%
Mar-12-24 09:55AM
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
(Zacks)
Mar-05-24 12:00PM
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
(Zacks)
Mar-04-24 08:45AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2023 Earnings Call Transcript
(Insider Monkey) -7.28%
07:30AM
Y-mAbs Appoints Oncology Executive Mary Tagliaferri, M.D. to its Board of Directors
(GlobeNewswire)
Mar-01-24 09:42PM
Q4 2023 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents) +11.92%
Feb-29-24 05:25PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
(Zacks)
04:37PM
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth in Q4 and Full Year 2023
(GuruFocus.com)
04:05PM
Y-mAbs Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Feb-22-24 10:00AM
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline
(Zacks)
Feb-16-24 07:30AM
Y-mAbs to Announce Fourth Quarter and Full Year 2023 Financial and Operating Results on February 29, 2024
(GlobeNewswire)
Feb-13-24 04:10AM
Y-mAbs Therapeutics, Inc. (YMAB) Moves 9.5% Higher: Will This Strength Last?
(Zacks)
Jan-02-24 04:05PM
Y-mAbs Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-13-23 04:05PM
Y-mAbs Therapeutics Added to the NASDAQ Biotechnology Index
(GlobeNewswire)
Dec-12-23 01:05AM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc
(GuruFocus.com)
Dec-03-23 03:04AM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc
(GuruFocus.com)
Nov-30-23 11:04PM
Director Biotech Wg's Strategic Investment in Y-mAbs Therapeutics Inc (YMAB)
(GuruFocus.com)
Nov-15-23 01:14PM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q3 2023 Earnings Call Transcript
(Insider Monkey)
01:33AM
Q3 2023 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
Nov-13-23 05:31PM
Y-mAbs Therapeutics Inc (YMAB) Reports Strong Revenue Growth Amidst Operational Streamlining
(GuruFocus.com) +9.84%
05:25PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates
(Zacks)
04:05PM
Y-mAbs Reports Third Quarter 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Nov-08-23 12:00PM
All You Need to Know About Y-mAbs Therapeutics, Inc. (YMAB) Rating Upgrade to Strong Buy
(Zacks)
Oct-31-23 07:05AM
Y-mAbs to Announce Third Quarter 2023 Financial and Operating Results on November 13, 2023
(GlobeNewswire)
Oct-18-23 04:05PM
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
(GlobeNewswire)
Oct-17-23 04:05PM
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
(GlobeNewswire)
Oct-16-23 04:05PM
Y-mAbs Announces Publication in Cancers
(GlobeNewswire)
Sep-21-23 04:05PM
Y-mAbs Announces Data to be Presented at the 55th Congress of the International Society of Pediatric Oncology
(GlobeNewswire)
Sep-06-23 04:05PM
Y-mAbs to Participate at Upcoming Investor Conferences in September
(GlobeNewswire)
Aug-23-23 09:55AM
Wall Street Analysts Think Y-mAbs Therapeutics, Inc. (YMAB) Could Surge 88.55%: Read This Before Placing a Bet
(Zacks)
Aug-13-23 06:25AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q2 2023 Earnings Call Transcript
(Insider Monkey)
Aug-10-23 05:15PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
(Zacks) +5.48% -9.90%
04:05PM
Y-mAbs Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
(GlobeNewswire)
Aug-02-23 04:05PM
Y-mAbs to Participate at Upcoming Investor Conferences
(GlobeNewswire)
Aug-01-23 04:05PM
Y-mAbs to Announce Second Quarter 2023 Financial and Operating Results on August 10, 2023
(GlobeNewswire)
Jul-26-23 12:35PM
Institutional owners may take dramatic actions as Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) recent 13% drop adds to one-year losses
(Simply Wall St.)
Jun-02-23 03:15PM
Y-mAbs Therapeutics (NASDAQ:YMAB investor three-year losses grow to 81% as the stock sheds US$53m this past week
(Simply Wall St.) +5.01%
May-26-23 09:00AM
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
(GlobeNewswire)
09:00AM
Y-mAbs Announces Presentation of GD2-SADA Study at ASCO
(GlobeNewswire)
May-23-23 09:00AM
Y-mAbs DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
(GlobeNewswire)
May-18-23 06:39AM
Daily Vickers Top Buyers & Sellers for 05/18/2023
(Argus Research) +8.39%
May-13-23 08:18AM
New Forecasts: Here's What Analysts Think The Future Holds For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)
(Simply Wall St.)
May-10-23 06:14AM
Y-mAbs Therapeutics First Quarter 2023 Earnings: Beats Expectations
(Simply Wall St.) +7.26%
02:52AM
Q1 2023 Y-mAbs Therapeutics Inc Earnings Call
(Thomson Reuters StreetEvents)
May-08-23 05:15PM
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Tops Revenue Estimates
(Zacks) +36.34%
04:01PM
Y-mAbs Reports First Quarter 2023 Financial Results and Recent Corporate Developments and Updates 2023 Financial Guidance
(GlobeNewswire)
May-01-23 10:01AM
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
(Zacks)
Apr-28-23 09:00AM
Y-mAbs to Announce First Quarter 2023 Financial and Operating Results on May 8, 2023
(GlobeNewswire) +5.46%
Apr-18-23 09:00AM
Y-mAbs Announces Presentation of Naxitamab data at AACR
(GlobeNewswire)
Apr-17-23 10:57AM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Surges 104% Yet Its Low P/S Is No Reason For Excitement
(Simply Wall St.)
Apr-05-23 07:44PM
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q4 2022 Earnings Call Transcript
(Insider Monkey)
09:55AM
Wall Street Analysts Believe Y-mAbs Therapeutics, Inc. (YMAB) Could Rally 111.13%: Here's is How to Trade
(Zacks)
09:00AM
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
(GlobeNewswire)
Apr-04-23 05:12AM
Y-mAbs Therapeutics, Inc. (YMAB) Surges 13.8%: Is This an Indication of Further Gains?
(Zacks)
Mar-30-23 05:25PM
Y-mAbs Therapeutics, Inc. (YMAB) Surpasses Q4 Earnings and Revenue Estimates
(Zacks) +52.28%
04:01PM
Y-mAbs Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
(GlobeNewswire)
02:42PM
Dow futures down 0.1%, Virgin Orbit tanks 41.2% after-hours
(Investing.com)
Mar-21-23 04:01PM
Y-mAbs to Announce 2022 Financial and Operating Results on March 30, 2023
(GlobeNewswire) -5.35%
Mar-15-23 10:22AM
Y-mAbs Therapeutics (NASDAQ:YMAB) Will Have To Spend Its Cash Wisely
(Simply Wall St.)
Feb-20-23 10:00AM
Analysts Estimate Apellis Pharmaceuticals, Inc. (APLS) to Report a Decline in Earnings: What to Look Out for
(Zacks)
Feb-16-23 10:01AM
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
(Zacks) -8.37%
07:57AM
With 51% ownership, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) boasts of strong institutional backing
(Simply Wall St.)
Feb-02-23 09:00AM
Y-mAbs and the European Medicines Agency Reach Agreement on the Pediatric Investigation Plan for Naxitamab
(GlobeNewswire)
Jan-05-23 10:34AM
Y-mAbs Therapeutics Plans To Deprioritize Omburtamab For Pediatric Cancer, Cuts One Third Of Workforce
(Benzinga) -7.83%
Jan-04-23 04:01PM
Y-mAbs Announces Restructuring Plan and Provides Financial Outlook Following Complete Response Letter from FDA
(GlobeNewswire) +6.24%
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer. Its services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gad ThomasCHIEF BUSINESS OFFICERSep 19 '24Option Exercise4.3822,831100,000181,531Sep 20 04:15 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 13 '24Sale13.4765,000875,55097,681Sep 17 08:05 PM
Gad ThomasCHIEF BUSINESS OFFICERSep 16 '24Sale12.9730,000389,10067,681Sep 17 08:05 PM
Thomas GadOfficerSep 13 '24Proposed Sale13.74100,0001,374,000Sep 13 04:19 PM
Ber GerardDirectorSep 03 '24Proposed Sale13.8313,950192,928Sep 03 05:00 PM
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERAug 28 '24Option Exercise4.3850,000219,00085,600Aug 30 04:15 PM
Lund-Hansen TorbenSVP & CHIEF TECHNICAL OFFICERAug 28 '24Sale15.3750,000768,50035,600Aug 30 04:15 PM
Lund-Hansen TorbenOfficerAug 28 '24Proposed Sale15.3750,000768,432Aug 28 05:12 PM
Wilms JorisSVP & CHIEF OPERATING OFFICERAug 26 '24Sale14.695,00073,45030,600Aug 27 05:05 PM
Wilms JorisOfficerAug 26 '24Proposed Sale14.695,00073,450Aug 26 04:12 PM
Ber GerardDirectorJun 10 '24Sale12.007228,6641,608Jun 11 07:54 PM
Gad ThomasCHIEF BUSINESS OFFICERJun 10 '24Sale12.0335,000421,050197,681Jun 11 07:53 PM
Gad ThomasCHIEF BUSINESS OFFICERJun 11 '24Sale12.0035,000420,000162,681Jun 11 07:53 PM
Kruse BoEVP, CFO, SECRY & TREAS.May 31 '24Option Exercise2.0031,37162,742242,248May 31 09:36 PM
Kruse BoEVP, CFO, SECRY & TREAS.May 30 '24Option Exercise2.0028,62957,258239,506May 31 09:36 PM
Kruse BoEVP, CFO, SECRY & TREAS.May 31 '24Sale12.0731,371378,648210,877May 31 09:36 PM
Kruse BoEVP, CFO, SECRY & TREAS.May 30 '24Sale12.0328,629344,407210,877May 31 09:36 PM
Gad ThomasCHIEF BUSINESS OFFICERMay 21 '24Sale12.0025,000300,000240,032May 23 06:54 PM
Gad ThomasCHIEF BUSINESS OFFICERMay 23 '24Sale13.007,35195,563232,681May 23 06:54 PM
Rajah VigneshSVP & CHIEF MEDICAL OFFICERMar 05 '24Sale16.531,71128,28333,889Mar 07 05:02 PM
Gad ThomasCHIEF BUSINESS OFFICERMar 05 '24Sale16.443,90064,116158,700Mar 07 05:01 PM
Smith Susan LauraSVP & CHIEF COMMERCIAL OFFICERMar 05 '24Sale16.551,68227,83733,918Mar 07 04:59 PM
Gad ThomasChief Business OfficerDec 21 '23Option Exercise2.0050,000100,000140,500Dec 26 04:15 PM
Gad ThomasChief Business OfficerDec 14 '23Sale6.8350,000341,500315,032Dec 15 07:40 PM
Gad ThomasChief Business OfficerDec 15 '23Sale6.6150,000330,500265,032Dec 15 07:40 PM
Gad ThomasChief Business OfficerDec 13 '23Sale6.5850,000329,000365,032Dec 15 07:40 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.